This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rini, B. I. Articles by Stadler, W. M. Search for Related Content PubMed PubMed Citation Articles by Rini, B. I. Articles by Stadler, W. M. Social Bookmarking                            What's this?

Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer

From the Section of Hematology/Oncology, University of Chicago Hospitals; University of Chicago Cancer Research Center, Chicago; Decatur Memorial Hospital, Decatur, IL; and Memorial Hospital, South Bend, IN.

Address reprint requests to Brian I. Rini, MD, University of Chicago Medical Center, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637-1470; email brini{at}medicine.bsd.uchicago.edu

PURPOSE: To determine the clinical response rate of the combination of weekly intravenous (IV) gemcitabine with continuous infusion fluorouracil (5-FU) in patients with metastatic renal cell carcinoma (RCC).

PATIENTS AND METHODS: Between June 1998 and February 1999, 41 patients with metastatic RCC were enrolled onto this multi-institutional phase II study of gemcitabine 600 mg/m² over 30 minutes on days 1, 8, and 15 and 5-FU 150 mg/m²/d via continuous IV infusion through a permanent catheter on days 1 to 21 of a 28-day cycle. Patients had a Cancer and Leukemia Group B performance status of 0 or 1, with a median time since diagnosis of metastatic disease of 10 months (range, 0 to 129 months). Thirty-three patients (80%) had multiple metastatic sites, and 34 patients (83%) had prior chemotherapy or immunotherapy.

RESULTS: Of the 39 assessable patients, there were no complete responses but seven partial responses (objective response rate = 17%; 95% confidence interval, 8% to 34%). Five minor responses (25% to 50% decreased tumor size) were also observed. The duration of response for the seven partial responders was 2, 3, 7, 8, 10, 11, and 14 months. Median progression-free survival for the gemcitabine/5-FU group was 28.7 weeks versus 8 weeks for a similar cohort of patients treated on previous phase II studies at the University of Chicago (P = .008). The regimen was well tolerated, with fatigue, mucositis, nausea/vomiting, and grade 2 hematologic toxicities being most common.

CONCLUSION: Weekly gemcitabine with continuous infusion 5-FU is an active combination in patients with metastatic RCC. Therapy was well tolerated and produced an improvement in progression-free survival over historical controls.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Jonasch, C. G. Wood, S. F. Matin, S.-M. Tu, L. C. Pagliaro, P. G. Corn, A. Aparicio, P. Tamboli, R. E. Millikan, X. Wang, et al. Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., September 1, 2009; 27(25): 4076 - 4081. [Abstract] [Full Text] [PDF]

				M. Sumitomo, F. Koizumi, T. Asano, A. Horiguchi, K. Ito, T. Asano, T. Kakizoe, M. Hayakawa, and Y. Matsumura Novel SN-38-Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression Cancer Res., March 15, 2008; 68(6): 1631 - 1635. [Abstract] [Full Text] [PDF]

				D Santini, V Virzi, B Vincenzi, L Rocci, V Leoni, and G Tonini A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients Ann. Onc., March 1, 2007; 18(3): 576 - 580. [Abstract] [Full Text] [PDF]

				P. Schoffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P. Wolter, S. Joniau, T. Roskams, and H. Van Poppel Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review Ann. Onc., August 1, 2006; 17(8): 1185 - 1196. [Abstract] [Full Text] [PDF]

				A. A. Desai, R. L. Schilsky, A. Young, L. Janisch, W. M. Stadler, N. J. Vogelzang, S. Cadden, J. A. Wright, and M. J. Ratain A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors Ann. Onc., June 1, 2005; 16(6): 958 - 965. [Abstract] [Full Text] [PDF]

				P. Thompson and M. Fishman Management of Metastatic Renal Cancer J Natl Compr Canc Netw, January 1, 2005; 3(1): 105 - 113. [Abstract] [PDF]

				S. Negrier, D. Perol, C. Menetrier-Caux, B. Escudier, M. Pallardy, A. Ravaud, J.-Y. Douillard, C. Chevreau, C. Lasset, and J.-Y. Blay Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6--From the Groupe Francais d'Immunotherapie J. Clin. Oncol., June 15, 2004; 22(12): 2371 - 2378. [Abstract] [Full Text] [PDF]

				R. J. Motzer, J. Bacik, L. H. Schwartz, V. Reuter, P. Russo, S. Marion, and M. Mazumdar Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., February 1, 2004; 22(3): 454 - 463. [Abstract] [Full Text] [PDF]

				J. A. Sosman Targeting of the VHL-Hypoxia-Inducible Factor-Hypoxia-Induced Gene Pathway for Renal Cell Carcinoma Therapy J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2695 - 2702. [Abstract] [Full Text] [PDF]

				S. Negrier, B. Escudier, F. Gomez, J.-Y. Douillard, A. Ravaud, C. Chevreau, M. Buclon, D. Perol, and C. Lasset Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie Ann. Onc., September 1, 2002; 13(9): 1460 - 1468. [Abstract] [Full Text] [PDF]

				C. M. George, N. J. Vogelzang, B. I. Rini, F. J. Geoffroy, P. Kollipara, and W. M. Stadler A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma Ann. Onc., January 19, 2002; 13(1): 116 - 120. [Abstract] [Full Text] [PDF]

				R. L. Schilsky, D. Bertucci, N. J. Vogelzang, H. L. Kindler, and M. J. Ratain Dose-Escalating Study of Capecitabine Plus Gemcitabine Combination Therapy in Patients With Advanced Cancer J. Clin. Oncol., January 15, 2002; 20(2): 582 - 587. [Abstract] [Full Text] [PDF]